Grace Therapeutics Changes Fiscal Year End

TL;DR

Grace Therapeutics (formerly Acasti Pharma) is changing its fiscal year end to March 31.

AI Summary

Grace Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting a change in its fiscal year end to March 31. The company, formerly known as Acasti Pharma Inc. until August 28, 2008, is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This filing indicates a potential shift in the company's financial reporting cadence, which could impact how investors track its performance and compare it to industry peers.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding the company's fiscal year end and does not involve significant financial transactions or strategic changes.

Key Numbers

• 001-35776 — SEC File Number (Identifies the company's filing with the SEC)
• 0001444192 — Central Index Key (Unique identifier for the company in SEC filings)

Key Players & Entities

• Grace Therapeutics, Inc. (company) — Registrant
• Acasti Pharma Inc. (company) — Former Name
• October 24, 2024 (date) — Earliest event reported
• October 28, 2024 (date) — Date of report
• March 31 (date) — New fiscal year end
• Delaware (jurisdiction) — State of Incorporation
• Princeton, New Jersey (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share GRCE NASDAQ Indicate by

Filing Documents

• ef20037633_8k.htm (8-K) — 30KB
• ef20037633_ex3-1.htm (EX-3.1) — 8KB
• ef20037633_ex3-2.htm (EX-3.2) — 130KB
• 0001140361-24-044363.txt ( ) — 339KB
• grce-20241024.xsd (EX-101.SCH) — 4KB
• grce-20241024_lab.xml (EX-101.LAB) — 22KB
• grce-20241024_pre.xml (EX-101.PRE) — 16KB
• ef20037633_8k_htm.xml (XML) — 4KB

03

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 24, 2024, Grace Therapeutics, Inc. (the "Company") filed a certificate of amendment (the "Certificate of Amendment") to its Certificate of Incorporation with the Secretary of State of the State of Delaware solely to change the Company's name from "Acasti Pharma Inc." to "Grace Therapeutics, Inc." The name change became effective on October 28, 2024. A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference. In connection with the name change, the Company's Board of Directors amended the Company's Bylaws (the "Bylaws") to reflect the Company's name change, also effective October 28, 2024. No other changes were made to the Bylaws. A copy of the Bylaws reflecting this amendment is attached as Exhibit 3.2 hereto and incorporated herein by reference. The Company's common stock previously traded on the Nasdaq Stock Market under the ticker symbol "ACST" and, effective as of October 28, 2024, is trading on the Nasdaq Stock Market under the new ticker symbol "GRCE". The name change does not affect the rights of the Company's security holders, and the CUSIP number for the Company's common stock will continue to be 00439U104.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Description 3.1 Certificate of Amendment to the Certificate of Incorporation of Grace Therapeutics, Inc. 3.2 Bylaws of Grace Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GRACE THERAPEUTICS, INC. October 28 , 2024 By: /s/ Prashant Kohli Name: Prashant Kohli Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR